These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 2514171)

  • 1. Synergy of Nocardia rubra cell wall skeleton and interleukin 2 in the in vivo induction of murine lymphokine-activated killer cell activity.
    Kawase I; Komuta K; Shirasaka T; Hara H; Tanio Y; Watanabe M; Saito S; Ikeda T; Masuno T; Kishimoto S
    Jpn J Cancer Res; 1989 Nov; 80(11):1089-97. PubMed ID: 2514171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of murine lymphokine-activated killer cell induction by a factor produced by Nocardia rubra cell wall skeleton-stimulated T cells.
    Kawase I; Shirasaka T; Ikeda T; Hara H; Tanio Y; Watanabe M; Saito S; Masuno T; Kishimoto S; Yamamura Y
    Jpn J Cancer Res; 1989 Nov; 80(11):1098-105. PubMed ID: 2481664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
    Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
    Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentative effect of Nocardia rubra cell-wall skeleton on the induction of human lymphokine-activated killer (LAK) cells by the production of LAK cell helper factor(s).
    Shirasaka T; Kawase I; Okada M; Kitahara M; Ikeda T; Komuta K; Hosoe S; Yokota S; Masuno T; Kishimoto S
    Cancer Immunol Immunother; 1989; 30(4):195-204. PubMed ID: 2598189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentative effect of Nocardia rubra cell-wall skeleton (N-CWS) on lymphokine-activated killer (LAK) cell induction.
    Yokota S; Shirasaka T; Nishikawa H; Hosoe S; Ikeda T; Komuta K; Kawase I; Masuno T; Ogura T; Kishimoto S
    Cancer Immunol Immunother; 1988; 26(1):11-7. PubMed ID: 3257899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma.
    Wang Y; Qian XJ; Hadley HR; Lau BH
    Mol Biother; 1992 Sep; 4(3):143-6. PubMed ID: 1445669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.
    Chao TY; Ohnishi H; Chu TM
    Mol Biother; 1989; 1(6):318-22. PubMed ID: 2610950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of endogenous lymphokine-activated killer activity by combined administration of lentinan and interleukin 2.
    Suzuki M; Higuchi S; Taki Y; Taki S; Miwa K; Hamuro J
    Int J Immunopharmacol; 1990; 12(6):613-23. PubMed ID: 2272726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
    Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW
    Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective in vivo induction of lymphokine-activated killer (LAK) cells by pretreatment with a streptococcal preparation, OK-432.
    Shimoda K; Saito T; Kobayashi M; Nomoto K
    Biotherapy; 1992; 5(1):63-9. PubMed ID: 1389903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of tumoricidal macrophages from bone marrow cells of normal mice or mice bearing a colony-stimulating-factor-producing tumor.
    Hosoe S; Ogura T; Hayashi S; Komuta K; Ikeda T; Shirasaka T; Kawase I; Masuno T; Kishimoto S
    Cancer Immunol Immunother; 1989; 28(2):116-22. PubMed ID: 2645051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of LAK-like cells in the peritoneal cavity of mice by inactivated Candida albicans.
    Scaringi L; Cornacchione P; Rosati E; Boccanera M; Cassone A; Bistoni F; Marconi P
    Cell Immunol; 1990 Sep; 129(2):271-87. PubMed ID: 2166624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.
    Iho S; Shau HY; Golub SH
    Cell Immunol; 1991 Jun; 135(1):66-77. PubMed ID: 2018984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
    J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated effector cells: modulation of activity by cytokines.
    Mehta S; Flanagan P; Blackinton D; Wanebo H
    Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
    Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
    Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.